ECSP22008993A - Derivados de alcohol como abridores del canal de potasio kv7 - Google Patents

Derivados de alcohol como abridores del canal de potasio kv7

Info

Publication number
ECSP22008993A
ECSP22008993A ECSENADI20228993A ECDI202208993A ECSP22008993A EC SP22008993 A ECSP22008993 A EC SP22008993A EC SENADI20228993 A ECSENADI20228993 A EC SENADI20228993A EC DI202208993 A ECDI202208993 A EC DI202208993A EC SP22008993 A ECSP22008993 A EC SP22008993A
Authority
EC
Ecuador
Prior art keywords
potassium channel
alcohol derivatives
channel openers
compounds
potassium channels
Prior art date
Application number
ECSENADI20228993A
Other languages
English (en)
Inventor
Debasis Das
Mario Rottländer
Xiaofang Wang
Shu Chen
Jian Hong
Anette Sams
Krestian Larsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP22008993A publication Critical patent/ECSP22008993A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv7. Los diferentes aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y usos de los compuestos para tratar trastornos que responden a la activación de los canales de potasio Kv7
ECSENADI20228993A 2019-08-02 2022-02-04 Derivados de alcohol como abridores del canal de potasio kv7 ECSP22008993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15

Publications (1)

Publication Number Publication Date
ECSP22008993A true ECSP22008993A (es) 2022-03-31

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20228993A ECSP22008993A (es) 2019-08-02 2022-02-04 Derivados de alcohol como abridores del canal de potasio kv7

Country Status (18)

Country Link
EP (1) EP4007634A1 (es)
JP (1) JP2022543203A (es)
KR (1) KR20220041084A (es)
CN (1) CN114206830A (es)
AU (1) AU2020325517A1 (es)
BR (1) BR112021006324A2 (es)
CA (1) CA3148719A1 (es)
CL (1) CL2022000221A1 (es)
CO (1) CO2022000080A2 (es)
CR (1) CR20220028A (es)
DO (1) DOP2022000026A (es)
EC (1) ECSP22008993A (es)
IL (1) IL290193A (es)
JO (1) JOP20220017A1 (es)
MX (1) MX2022001063A (es)
PE (1) PE20220345A1 (es)
WO (1) WO2021023617A1 (es)
ZA (1) ZA202109598B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290167A1 (en) 2000-05-26 2003-03-12 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
AU2001268303A1 (en) 2000-06-11 2001-12-24 Du Pont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
EA017915B1 (ru) 2006-02-07 2013-04-30 Х. Лундбекк А/С Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
EA201070189A1 (ru) 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
HUE063567T2 (hu) * 2018-02-20 2024-01-28 H Lundbeck As Alkoholszármazékok mint KV7 káliumcsatorna nyitók

Also Published As

Publication number Publication date
ZA202109598B (en) 2024-04-24
AU2020325517A1 (en) 2022-02-24
CN114206830A (zh) 2022-03-18
CO2022000080A2 (es) 2022-01-17
KR20220041084A (ko) 2022-03-31
DOP2022000026A (es) 2022-03-31
MX2022001063A (es) 2022-02-14
EP4007634A1 (en) 2022-06-08
CL2022000221A1 (es) 2022-10-07
IL290193A (en) 2022-03-01
CR20220028A (es) 2022-03-02
JOP20220017A1 (ar) 2023-01-30
WO2021023617A1 (en) 2021-02-11
BR112021006324A2 (pt) 2022-02-15
JP2022543203A (ja) 2022-10-11
PE20220345A1 (es) 2022-03-14
CA3148719A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018003425A1 (es) Composiciones de cannabidiol y usos de las mismas.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
MD3755684T2 (ro) Derivați de alcool ca deschizători ai canalelor de potasiu Kv7
ECSP22051247A (es) Fluoroalquil-oxadiazoles y sus usos
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2020003354A1 (es) Compuestos
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CR20170591A (es) Benzamidas sustituidas y métodos para utilizarlas
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CU20210077A7 (es) Extractos bacterianos estables como fármacos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2020002038A1 (es) Oligonucleótidos para modular la expresión de tmem106b.
NI202000042A (es) Polimorfos
CL2019002031A1 (es) Moduladores del canal de potasio.
ECSP22008993A (es) Derivados de alcohol como abridores del canal de potasio kv7
CL2021001123A1 (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.
ECSP22003596A (es) Moduladores del receptor de nmda
CU20160058A7 (es) Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat